CDKN1B and CCNA2

Number of citations of the paper that reports this interaction (PubMedID 17254966)
157

Data Source:
HPRD (in vitro)

		CDKN1B	CCNA2
Description		cyclin dependent kinase inhibitor 1B	cyclin A2
Image
GO Annotations	Cellular Component	Nucleus Nucleoplasm Cytoplasm Endosome Cytosol Cul4A-RING E3 Ubiquitin Ligase Complex Intracellular Membrane-bounded Organelle	Cyclin-dependent Protein Kinase Holoenzyme Complex Female Pronucleus Male Pronucleus Nucleus Nucleoplasm Cytoplasm Cytosol Cyclin A2-CDK2 Complex
	Molecular Function	Protein Kinase Inhibitor Activity Cyclin-dependent Protein Serine/threonine Kinase Inhibitor Activity Protein Binding Protein Kinase Binding Protein Phosphatase Binding Cyclin Binding Hsp70 Protein Binding Protein-containing Complex Binding Chaperone Binding	Protein Binding Cyclin-dependent Protein Serine/threonine Kinase Regulator Activity Protein Kinase Binding Protein Domain Specific Binding
	Biological Process	Regulation Of Cyclin-dependent Protein Serine/threonine Kinase Activity G1/S Transition Of Mitotic Cell Cycle Response To Hypoxia Placenta Development Potassium Ion Transport DNA Damage Response, Signal Transduction By P53 Class Mediator Resulting In Cell Cycle Arrest Regulation Of Exit From Mitosis Notch Signaling Pathway Heart Development Sensory Perception Of Sound Positive Regulation Of Cell Population Proliferation Negative Regulation Of Cell Population Proliferation Response To Xenobiotic Stimulus Response To Glucose Positive Regulation Of Cell Death Negative Regulation Of Cell Growth Positive Regulation Of Microtubule Polymerization Response To Estradiol Negative Regulation Of Kinase Activity Negative Regulation Of Phosphorylation Negative Regulation Of Apoptotic Process Response To Amino Acid Response To Peptide Hormone Positive Regulation Of Protein Catabolic Process Negative Regulation Of Cyclin-dependent Protein Serine/threonine Kinase Activity Positive Regulation Of Cyclin-dependent Protein Serine/threonine Kinase Activity Negative Regulation Of Cell Cycle Negative Regulation Of Transcription, DNA-templated Negative Regulation Of Mitotic Cell Cycle Response To Cadmium Ion Autophagic Cell Death Inner Ear Development Negative Regulation Of Cellular Component Movement Regulation Of Cell Cycle Negative Regulation Of Epithelial Cell Proliferation Involved In Prostate Gland Development Cellular Response To Antibiotic Cellular Response To Lithium Ion Cellular Response To Organic Cyclic Compound Cellular Senescence Regulation Of Lens Fiber Cell Differentiation Regulation Of Cell Cycle G1/S Phase Transition Negative Regulation Of Cyclin-dependent Protein Kinase Activity Negative Regulation Of Vascular Associated Smooth Muscle Cell Proliferation Negative Regulation Of Cardiac Muscle Tissue Regeneration	Regulation Of Cyclin-dependent Protein Serine/threonine Kinase Activity G2/M Transition Of Mitotic Cell Cycle Regulation Of DNA Replication Ras Protein Signal Transduction Histone Phosphorylation Animal Organ Regeneration Response To Glucagon Cellular Response To Platelet-derived Growth Factor Stimulus Cellular Response To Leptin Stimulus Mitotic Cell Cycle Phase Transition Cell Cycle G1/S Phase Transition Positive Regulation Of Transcription, DNA-templated Positive Regulation Of Fibroblast Proliferation Cell Division Cellular Response To Cocaine Cellular Response To Luteinizing Hormone Stimulus Cellular Response To Estradiol Stimulus Cellular Response To Hypoxia Cellular Response To Nitric Oxide Cochlea Development Cellular Response To Insulin-like Growth Factor Stimulus
Pathways		SCF(Skp2)-mediated degradation of p27/p21 AKT phosphorylates targets in the cytosol Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence RHO GTPases activate CIT Constitutive Signaling by AKT1 E17K in Cancer TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Cyclin E associated events during G1/S transition Cyclin D associated events in G1 p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry PTK6 Regulates Cell Cycle FLT3 Signaling FOXO-mediated transcription of cell cycle genes Estrogen-dependent nuclear events downstream of ESR-membrane signaling Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 G0 and Early G1 Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes Telomere Extension By Telomerase Cdc20:Phospho-APC/C mediated degradation of Cyclin A Regulation of APC/C activators between G1/S and early anaphase SCF(Skp2)-mediated degradation of p27/p21 Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Ub-specific processing proteases Processing of DNA double-strand break ends TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation G2 Phase Orc1 removal from chromatin CDK-mediated phosphorylation and removal of Cdc6 Cyclin A/B1/B2 associated events during G2/M transition Cyclin A/B1/B2 associated events during G2/M transition p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry
Drugs			4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine 6-O-Cyclohexylmethyl Guanine [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine 4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE (2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM 4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE Variolin B
Diseases
GWAS		Appendicular lean mass ( 33097823) Brain morphology (MOSTest) ( 32665545) Diastolic blood pressure ( 30487518) Mean arterial pressure ( 29403010 30487518) Metabolite levels ( 23823483) Monocyte percentage of white cells ( 32888494) Mosaic loss of chromosome Y (Y chromosome dosage) ( 31624269) Plateletcrit ( 32888494) Prostate cancer ( 31562322 29892016) Refractive error ( 32231278) Systemic lupus erythematosus ( 23273568 33272962) Systolic blood pressure ( 30487518) Type 2 diabetes ( 30297969)	Mean corpuscular hemoglobin ( 32888494)
Interacting Genes		73 interacting genes: ABL1 AKT1 ARHGDIA ARIH1 CAMK1 CASP8 CCNA1 CCNA2 CCNB1 CCND1 CCND2 CCND3 CCNE1 CCNE2 CDC34 CDK1 CDK2 CDK3 CDK4 CDK5 CKS1B COP1 COPS5 CUL1 CUL4A DCLRE1C GRB2 H1-1 H1-5 IRF1 KAT2B KPNA1 KPNA3 KPNA4 KPNA5 KPNA6 LYN MAPK10 MCM7 MTUS2 MYC NUP50 PIN1 PSMB1 RBX1 RCHY1 RNF123 RPS6KA1 SGK1 SIRT6 SKP1 SKP2 SPDYA SRC STMN1 TRAF2 TSC2 UBAC1 UBB UBE2B UBE2D2 UBE2I UBE2L3 UBE3A UCHL1 XPO1 YES1 YWHAB YWHAE YWHAG YWHAH YWHAQ YWHAZ	49 interacting genes: ARID4A BRCA1 BRCA2 BTG1 BUB1B CALM1 CDC20 CDC25C CDC6 CDK1 CDK2 CDK3 CDKN1A CDKN1B CDT1 DRD2 DTNBP1 E2F1 E2F3 FANCC FEN1 H1-1 H1-5 HERC5 HIRA ITGB3BP KAT2B MAD2L1 MAGEA11 MYBL2 NFYA PGR POLA1 PRC1 PSMD4 PTMA RAD23A RB1 RBL1 RBL2 RPA1 SKP1 SKP2 SP1 TAF1 TP53 TRAF3IP1 UBTF USP37
Entrez ID		1027	890
HPRD ID		02867	00453
Ensembl ID		ENSG00000111276	ENSG00000145386
Uniprot IDs		P46527 Q6I9V6	P20248
PDB IDs		1H27 1JSU 2AST 5UQ3 6ATH 6P8E 6P8F 6P8G 7B5L 7B5M 7B5R	1E9H 1FIN 1FVV 1GY3 1H1P 1H1Q 1H1R 1H1S 1H24 1H25 1H26 1H27 1H28 1JST 1JSU 1OGU 1OI9 1OIU 1OIY 1OKV 1OKW 1OL1 1OL2 1P5E 1PKD 1QMZ 1URC 1VYW 2BKZ 2BPM 2C4G 2C5N 2C5O 2C5V 2C5X 2C6T 2CCH 2CCI 2CJM 2I40 2IW6 2IW8 2IW9 2UUE 2UZB 2UZD 2UZE 2UZL 2V22 2WEV 2WFY 2WHB 2WIH 2WIP 2WMA 2WMB 2WPA 2WXV 2X1N 3EID 3EJ1 3EOC 3F5X 4BCK 4BCM 4BCN 4BCP 4CFM 4CFN 4CFU 4CFV 4CFW 4CFX 4EOI 4EOJ 4EOK 4EOL 4EOM 4EON 4EOO 4EOP 4EOQ 4EOR 4EOS 4FX3 5CYI 5IF1 5LMK 5NEV 6ATH 6GVA 6P3W 6Q6G 6Q6H 6RIJ 6SG4 7B5L 7B5R
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?